Literature DB >> 1698578

In vitro IgG rheumatoid factor production by CD5-negative murine B cells in response to immune complexes of lipopolysaccharide.

H Taguchi1, M Kanoh, N Takubo, S Kadota, K Kanazawa, T Shibata, S Utsumi.   

Abstract

We studied the in vitro production of rheumatoid factor (RF) by spleen cells of normal adult mice. IgG RF cross-reactive with rabbit IgG was produced in response to immune complexes of TNP-lipopolysaccharide (LPS) with murine IgG anti-TNP antibody in an Fc-specific manner, but not to a mixture of IgG and LPS. Antibody-uncomplexed LPS induced little IgG RF production, but suppressed the subsequent IgG RF response to antibody-complexed LPS, whereas IgM RF was induced by either LPS or antibody-complexed LPS. The IgG RF production followed as rapid a time course as IgM RF production; the rate of IgG RF production reached its maximum soon after a lag period of 1 day and declined after 5 days. Treatment of splenic B cells from BALB/c mice with anti-Ly-1.2 antibody and rabbit complement resulted in a selective reduction of IgM RF production by 90%, with little effect of IgG RF production. These results suggest that IgG RF is derived primarily from CD5- memory B cells which have been developed in normal mice by an unknown mechanism. Unlike the CD5+ precursor cells for IgM RF, these memory cells are unresponsive to polyclonal stimulation by LPS but are activated by simultaneous stimulation by aggregated Fc epitopes and the mitogenic stimulus from LPS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698578      PMCID: PMC1535172          DOI: 10.1111/j.1365-2249.1990.tb05415.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Effect of bacterial lipopolysaccharide on the in vitro secondary antibody response in mice. I. Description of the suppressive capacity of lipopolysaccharide.

Authors:  S M Walker; W O Weigle
Journal:  Cell Immunol       Date:  1978-03-01       Impact factor: 4.868

Review 2.  Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes.

Authors:  P Casali; A L Notkins
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

Review 3.  Normal, autoimmune, and malignant CD5+ B cells: the Ly-1 B lineage?

Authors:  K Hayakawa; R R Hardy
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

4.  Molecular cloning of Ly-1, a membrane glycoprotein of mouse T lymphocytes and a subset of B cells: molecular homology to its human counterpart Leu-1/T1 (CD5).

Authors:  H J Huang; N H Jones; J L Strominger; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

5.  In vitro IgM and IgM rheumatoid factor production in response to Staphylococcus aureus Cowan I and pokeweed mitogen: the contribution of CD5+ (Leu 1) B cells.

Authors:  J Karsh; R Goldstein; A I Lazarovits
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

6.  Rheumatoid factor secretion from human Leu-1+ B cells.

Authors:  R R Hardy; K Hayakawa; M Shimizu; K Yamasaki; T Kishimoto
Journal:  Science       Date:  1987-04-03       Impact factor: 47.728

7.  Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset.

Authors:  P Casali; S E Burastero; M Nakamura; G Inghirami; A L Notkins
Journal:  Science       Date:  1987-04-03       Impact factor: 47.728

8.  The role of surface IgD in the response to thymic-independent antigens.

Authors:  I M Zitron; D E Mosier; W E Paul
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

9.  Monoclonal anti-IgG autoantibodies derived from lipopolysaccharide-activated spleen cells of 129/Sv mice.

Authors:  J L Van Snick; P Coulie
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

10.  Induction of rheumatoid antibodies in the mouse. Regulated production of autoantibody in the secondary humoral response.

Authors:  D A Nemazee; V L Sato
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.